← Back to patent-cliff list
Clonidine
Tier C — Watch / tradeClonidine
Sollis Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：ADRA2, Imidazoline receptor
Indications (approved)：坐骨神经痛, Opioid dependence, Anaesthesia, 手术后恶心呕吐, Postoperative pain, 寒战, 肌肉骨骼系统疾病, 神经根病
Regional status
US
Discontinued
2023-06-19
EU
No progress
2022-06-17
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Clonidine?
Approved indications include: 坐骨神经痛, Opioid dependence, Anaesthesia, 手术后恶心呕吐, Postoperative pain, 寒战, 肌肉骨骼系统疾病, 神经根病.
When does the Clonidine patent expire?
No public expiry year is available for Clonidine yet; this page updates once verified.
How do I get a quote for Clonidine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21